Eli Lilly and Company (LLY) is a Healthcare · Drug Manufacturers - General company listed on NYSE. Price $1152.93 (+0.04%), Market cap $928.88B, P/E ratio 37.04, 52-week low–high $625.65 ~ $1109.94.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for color
Financial statements, price targets, institutional (13F) holdings and related news for Eli Lilly and Company are updated in real time on BlackAll Trade.
10 recent posts · 9 bullish · 0 bearish · 1 neutral.
Eli Lilly and Company trades at $1152.93 (+0.04%). Real-time quotes and charts are available on BlackAll Trade.
Eli Lilly and Company has a market cap of about $928.88B. Its P/E ratio is 37.04.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic h